Computer artwork of monoclonal antibodies, bi-specific T-cell engagers (BiTEs), acting against tumour cells. Blinatumomab (trade name) specifically ta

---

Computer artwork of monoclonal antibodies, bi-specific T-cell engagers (BiTEs), acting against tumour cells. Blinatumomab (trade name) specifically targets the CD19 antigen present on B cells. Blinatumomab enables a patient's T cells to recognize malignant B cells. A molecule of blinatumomab combines two binding sites: a CD3 site for T cells and a CD19 site for the target B cells. CD3 is part of the T cell receptor. The drug works by linking these two cell types and activating the T cell to exert cytotoxic activity on the target is used as a second-line treatment against acute lymphoblastic leukemia. The image shows a cancer cell (red, down left) and an immune cell (blue, upper right) connected by the Blinatumomab bi-specific antibody.

---

Size: 3750px × 5000px
Photo credit: © ALFRED PASIEKA/SCIENCE PHOTO LIBRARY / Alamy / Afripics
License: Licensed
Model Released: No

Keywords: -, -cell, -line, activating, activity, acute, adult, antibodies, antibody, antigen, artwork, bi-specific, binding, bites, blinatumomab, cancer, cd19, cd3, cell, cells, cells., cgi, combines, cut, cut-, cut-outs, cutout, cutouts, cytotoxic, digitally-generated, drug, engagers, illustration, image, leukaemia, leukemia, linking, lymphoblastic, malignant, molecule, monoclonal, outs, patients, potential, receptor, sites, target, therapeutic, treatment, tumor, tumour